Insider Transactions in Q4 2024 at Selecta Biosciences Inc (SELB)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,901
-5.38%
|
$69,624
$24.35 P/Share
|
|
Dec 10
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,901
+5.1%
|
$2,901
$1.41 P/Share
|
|
Dec 09
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
10,763
-9.12%
|
$269,075
$25.55 P/Share
|
|
Dec 09
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,763
+14.83%
|
$10,763
$1.41 P/Share
|
|
Nov 21
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
32,789
-39.12%
|
$524,624
$16.67 P/Share
|
|
Nov 21
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,789
+28.12%
|
$32,789
$1.41 P/Share
|
|
Nov 20
2024
|
Christopher M Jewell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,000
+25.95%
|
$42,000
$3.23 P/Share
|
|
Nov 20
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
5,700
-5.03%
|
$96,900
$17.69 P/Share
|
|
Nov 20
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,700
+9.13%
|
$5,700
$1.41 P/Share
|
|
Nov 19
2024
|
Michael Singer Director |
SELL
Bona fide gift
|
Direct |
28,821
-24.07%
|
-
|
|
Nov 19
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
200
-0.39%
|
$3,800
$19.5 P/Share
|
|
Nov 19
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+0.39%
|
$200
$1.41 P/Share
|
|
Nov 18
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
58,295
+0.34%
|
$1,049,310
$18.19 P/Share
|
|
Nov 18
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
34,400
-22.65%
|
$619,200
$18.39 P/Share
|
|
Nov 18
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,400
+28.71%
|
$34,400
$1.41 P/Share
|
|
Nov 15
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
277,246
+3.2%
|
$4,713,182
$17.09 P/Share
|
|
Nov 15
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
22,068
-30.19%
|
$375,156
$17.2 P/Share
|
|
Nov 15
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,068
+23.19%
|
$22,068
$1.41 P/Share
|
|
Nov 15
2024
|
Milos Miljkovic Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,000
-52.26%
|
$340,000
$17.14 P/Share
|
|
Nov 15
2024
|
Milos Miljkovic Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+34.32%
|
$60,000
$3.23 P/Share
|
|
Nov 15
2024
|
Christopher M Jewell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
16,065
-38.25%
|
$273,105
$17.06 P/Share
|
|
Nov 15
2024
|
Christopher M Jewell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,065
+27.66%
|
$48,195
$3.23 P/Share
|
|
Nov 14
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
96,399
+0.59%
|
$1,542,384
$16.58 P/Share
|
|
Nov 14
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
25,900
-17.87%
|
$414,400
$16.7 P/Share
|
|
Nov 14
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,900
+25.19%
|
$25,900
$1.41 P/Share
|
|
Nov 14
2024
|
Milos Miljkovic Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
35,000
-65.7%
|
$560,000
$16.13 P/Share
|
|
Nov 14
2024
|
Milos Miljkovic Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+39.65%
|
$105,000
$3.23 P/Share
|
|
Nov 14
2024
|
Christopher M Jewell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
36,050
-35.1%
|
$576,800
$16.68 P/Share
|
|
Nov 14
2024
|
Christopher M Jewell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,050
+36.77%
|
$108,150
$3.23 P/Share
|
|
Oct 11
2024
|
Murat Kalayoglu Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,518,373
+25.0%
|
-
|
|
Oct 11
2024
|
Elizabeth Hoge > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,518,373
+25.0%
|
-
|
|
Oct 04
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
80,301
+0.25%
|
$1,766,622
$22.8 P/Share
|
|
Oct 03
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
119,906
+0.3%
|
$2,398,120
$20.09 P/Share
|
|
Oct 02
2024
|
Timothy A Springer Director |
BUY
Other acquisition or disposition
|
Indirect |
317,879
+49.01%
|
-
|
|
Oct 02
2024
|
Timothy A Springer Director |
SELL
Other acquisition or disposition
|
Indirect |
2,119,193
-80.0%
|
-
|
|
Oct 02
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
5,514
+0.07%
|
$93,738
$17.38 P/Share
|
|
Oct 02
2024
|
Timothy A Springer Director |
BUY
Other acquisition or disposition
|
Direct |
1,801,314
+18.73%
|
-
|